Balchem Q2 record net sales $236.7M (+17% YoY), GAAP EPS $0.92, adj. EPS $1.07

BALCHEM CORP

2022-Q2 EPS reported $1.81 revenue$465,560,000

Record net sales $236.7M, up 17% YoY; GAAP EPS $0.92, adjusted EPS $1.07 (record).
Adjusted EBITDA $56.5M, up 12.6% YoY; all three segments posted sales growth.
Completed acquisition of Kappa (vitamin K2 manufacturer) on June 21, 2022; expands nutrition portfolio.
Entered new $550M revolving credit facility due 2027, replacing $500M facility due 2023.
Cash from operations $48.2M; net debt $357.4M, leverage ratio 1.8x.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.